ABSTRACT
Introducción: La tosferina ha aumentado su incidencia y severidad especialmente en lactantes, por lo que la vacunación de la embarazada se ha introducido como estrategia preventiva. La pandemia de la COVID-19 parece haber disminuido la incidencia de distintas enfermedades respiratorias. Métodos: Estudio retrospectivo entre 2012-2021, analizando la influencia de la vacunación de la embarazada y del primer año de la pandemia de la COVID-19 en los casos de tosferina. Resultados: Se incluyeron 960 pacientes de atención primaria y hospitalaria con sospecha de tosferina, con 130 casos diagnosticados (104 niños y 26 adultos). En el periodo posvacunal, se observó una disminución de casos y de severidad de la tosferina en niños menores de 6 meses y de los diagnósticos en mujeres adultas. No se detectó ningún paciente con tosferina durante el periodo de la COVID-19. Conclusión: Tanto la vacunación de la embarazada como el primer año de la pandemia de la COVID-19 han disminuido significativamente los casos de tosferina.(AU)
Background: Whooping cough has had an increased incidence and severity specially in infants and maternal immunization has been implemented as a prevention strategy. COVID-19 pandemic seems to decrease the incidence of other respiratory diseases. Methods: Retrospective study from 2012 to 2021 to assess the influence of pertussis maternal immunizations and the first year of COVID-19 pandemic in the cases of whooping cough. Results: 960 suspected cases from primary care and hospital, with 130 cases (104 children and 26 adults) being diagnosed of whooping cough. In the post-vaccination period, a reduction in the cases and severity in infants up to 6 months old was observed as well as in the pertussis diagnosis in adult women. There were no whooping cough cases during the COVID-19 period. Conclusions: Both the pertussis vaccination in pregnancy and the first year of the COVID-19 pandemic have decreased the number of pertussis cases.(AU)
Subject(s)
Humans , Female , Pregnancy , Pandemics , Betacoronavirus , Coronavirus Infections , Severe acute respiratory syndrome-related coronavirus , Pregnant Women , Vaccination , Whooping Cough , Vaccines/administration & dosage , Vaccines/adverse effects , Retrospective Studies , Microbiology , Communicable DiseasesABSTRACT
BACKGROUND: Whooping cough has had an increased incidence and severity specially in infants and maternal immunization has been implemented as a prevention strategy. COVID-19 pandemic seems to decrease the incidence of other respiratory diseases. METHODS: Retrospective study from 2012 to 2021 to assess the influence of pertussis maternal immunizations and the first year of COVID-19 pandemic in the cases of whooping cough. RESULTS: 960 suspected cases from primary care and hospital, with 130 cases (104 children and 26 adults) being diagnosed of whooping cough. In the post-vaccination period, a reduction in the cases and severity in infants up to 6 months old was observed as well as in the pertussis diagnosis in adult women. There were no whooping cough cases during the COVID-19 period. CONCLUSIONS: Both the pertussis vaccination in pregnancy and the first year of the COVID-19 pandemic have decreased the number of pertussis cases.
Subject(s)
COVID-19 , Whooping Cough , Infant , Child , Adult , Pregnancy , Female , Humans , Pertussis Vaccine , Whooping Cough/epidemiology , Whooping Cough/prevention & control , COVID-19/epidemiology , COVID-19/prevention & control , Cough/epidemiology , Retrospective Studies , PandemicsABSTRACT
Background: Whooping cough has had an increased incidence and severity specially in infants and maternal immunization has been implemented as a prevention strategy. COVID-19 pandemic seems to decrease the incidence of other respiratory diseases. Methods: Retrospective study from 2012 to 2021 to assess the influence of pertussis maternal immunizations and the first year of COVID-19 pandemic in the cases of whooping cough. Results: 960 suspected cases from primary care and hospital, with 130 cases (104 children and 26 adults) being diagnosed of whooping cough. In the post-vaccination period, a reduction in the cases and severity in infants up to 6 months old was observed as well as in the pertussis diagnosis in adult women. There were no whooping cough cases during the COVID-19 period. Conclusions: Both the pertussis vaccination in pregnancy and the first year of the COVID-19 pandemic have decreased the number of pertussis cases.
ABSTRACT
BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of the annual number of moderate-to-severe exacerbations compared with the baseline period. RESULTS: Of the 484 patients included, 101 (20.9%) reached 6 years of treatment. The mean ± standard deviation number of exacerbations decreased during the first year of treatment (7.9 ± 6.6 to 1.1 ± 2.0, P < .001) and remained likewise for up to 6 years. The other clinical parameters assessed also improved significantly during the first year and stabilized or continued to improve thereafter. The percentage of patients experiencing adverse events was consistently low, and the main reason for discontinuation was good disease evolution. CONCLUSION: In this large, long-term, observational study, moderate-to-severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long term, along with a good safety profile. Our results position omalizumab as an effective long-term treatment in pediatric patients with severe persistent allergic asthma.
Subject(s)
Anti-Asthmatic Agents/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Asthma , Omalizumab/therapeutic use , Anti-Asthmatic Agents/adverse effects , Antibodies, Monoclonal, Humanized/adverse effects , Asthma/drug therapy , Child , Humans , Omalizumab/adverse effects , Retrospective Studies , Treatment OutcomeABSTRACT
No disponble
Subject(s)
Humans , Child, Preschool , Child , Tuberculosis, Multidrug-Resistant/diagnosis , Tuberculosis, Multidrug-Resistant/therapy , Isoniazid/therapeutic use , Rifampin/therapeutic use , Risk Factors , Prospective Studies , Communicable Period , Radiography, ThoracicSubject(s)
Antitubercular Agents/therapeutic use , Isoniazid/therapeutic use , Rifampin/therapeutic use , Tuberculosis, Multidrug-Resistant/drug therapy , Antitubercular Agents/pharmacology , Child , Child, Preschool , Contact Tracing , Drug Resistance, Multiple, Bacterial , Drug Therapy, Combination , Ethambutol/therapeutic use , Humans , Isoniazid/pharmacology , Microbial Sensitivity Tests , Mycobacterium tuberculosis/drug effects , Prospective Studies , Pyrazinamide/therapeutic use , Rifampin/pharmacology , Spain/epidemiology , Tuberculosis, Multidrug-Resistant/epidemiologyABSTRACT
No disponible
